Literature DB >> 15634010

Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.

Christine B Breitenlechner1, Walter-Gunar Friebe, Emmanuel Brunet, Guido Werner, Klaus Graul, Ulrike Thomas, Klaus-Peter Künkele, Wolfgang Schäfer, Michael Gassel, Dirk Bossemeyer, Robert Huber, Richard A Engh, Birgit Masjost.   

Abstract

Protein kinase B (PKB)-selective inhibitors were designed, synthesized, and cocrystallized using the AGC kinase family protein kinase A (PKA, often called cAMP-dependent protein kinase); PKA has been used as a surrogate for other members of this family and indeed for protein kinases in general. The high homology between PKA and PKB includes very similar ATP binding sites and hence similar binding pockets for inhibitors, with only few amino acids that differ between the two kinases. A series of these sites were mutated in PKA in order to improve the surrogate model for a design of PKB-selective inhibitors. Namely, the PKA to PKB exchanges F187L and Q84E enable the design of the selective inhibitors described herein which mimic ATP but extend further into a site not occupied by ATP. In this pocket, selectivity over PKA can be achieved by the introduction of bulkier substituents. Analysis of the cocrystal structures and binding studies were performed to rationalize the selectivity and improve the design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634010     DOI: 10.1021/jm049701n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.

Authors:  Mei Hua Gao; Tong Tang; Tracy Guo; Atsushi Miyanohara; Toshitaka Yajima; Kersi Pestonjamasp; James R Feramisco; H Kirk Hammond
Journal:  J Biol Chem       Date:  2008-10-05       Impact factor: 5.157

2.  Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.

Authors:  David M Thal; Raymond Y Yeow; Christian Schoenau; Jochen Huber; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2011-05-19       Impact factor: 4.436

3.  Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).

Authors:  Tatiana McHardy; John J Caldwell; Kwai-Ming Cheung; Lisa J Hunter; Kevin Taylor; Martin Rowlands; Ruth Ruddle; Alan Henley; Alexis de Haven Brandon; Melanie Valenti; Thomas G Davies; Lynsey Fazal; Lisa Seavers; Florence I Raynaud; Suzanne A Eccles; G Wynne Aherne; Michelle D Garrett; Ian Collins
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

4.  Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation.

Authors:  Tomoko Sunami; Noel Byrne; Ronald E Diehl; Kaoru Funabashi; Dawn L Hall; Mari Ikuta; Sangita B Patel; Jennifer M Shipman; Robert F Smith; Ikuko Takahashi; Joan Zugay-Murphy; Yoshikazu Iwasawa; Kevin J Lumb; Sanjeev K Munshi; Sujata Sharma
Journal:  J Biol Chem       Date:  2009-10-28       Impact factor: 5.157

5.  How Far Are We from the Rapid Prediction of Drug Resistance Arising Due to Kinase Mutations?

Authors:  Mehmet Erguven; Tülay Karakulak; M Kasim Diril; Ezgi Karaca
Journal:  ACS Omega       Date:  2021-01-04

6.  Structures of PKA-phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy.

Authors:  Juan Qin; Jingfeng Zhang; Lianyun Lin; Omid Haji-Ghassemi; Zhi Lin; Kenneth J Woycechowsky; Filip Van Petegem; Yan Zhang; Zhiguang Yuchi
Journal:  Elife       Date:  2022-03-17       Impact factor: 8.713

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.